Clinical trials: Plasmodium Vivax Infection
Plasmodium Infection
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia
This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria…
- Trial name
- NCT05117567
- Testing
- Personal protection package
- Volunteers
- 5,868 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria, Malaria Vivax
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria
The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P.
- Conditions
- Malaria, Malaria Vivax, Radical Cure
- Trial name
- SJ733-2002 (NCT07430592)
- Testing
- CQ/TQ, SJ733 (3-day)/TQ, SJ733 (2-day ) /TQ
- Where
- Peru
- Volunteers
- 104 people
- Sponsor
- R. Kiplin Guy
Uncomplicated Malaria
Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07403643
- Testing
- Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 60 people
- Sponsor
- Curtin University
Malaria, Vivax
Serological Screen and Treat Trial for Plasmodium Vivax
This is a clinical trial to evaluate an experimental serological diagnostic technique intended to identify people at high risk of having dormant malaria parasites in their liver.
- Trial name
- SSAT (NCT04223674)
- Testing
- Serological screen and treat
- Where
- Indonesia
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Healthy Lactating Women
Tafenoquine and Primaquine in Colostrum and Breast Milk
Each year almost a million infants are born small for gestational age due to malaria infection in pregnancy. These infants are at risk for stillbirth or neonatal death, and being born too small predisposes the survivors to…
- Trial name
- TBM (NCT04984759)
- Testing
- Primaquine, Tafenoquine
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Oxford
Vivax Malaria
Study on the Treatment of Vivax Malaria
This is a randomised open label trial with follow up for 1 year. 660 adults and children above 6 months diagnosed with acute Plasmodium vivax will be randomised into 3 groups, either chloroquine, artesunate, or…
- Trial name
- VHX (NCT01074905)
- Testing
- Artesunate, Chloroquine, Chloroquine/Primaquine
- Where
- Thailand
- Volunteers
- 655 people
- Sponsor
- University of Oxford
MALARIA, FEVER
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
The study is a randomized open label clinical trial to verify the reproducibility of a sporozoite challenge model for Plasmodium vivax in humans.
- Conditions
- MALARIA, FEVER, Sweating Fever, Chills
- Trial name
- NCT00367380
- Testing
- 413ABM, 414WRR, 418JAL
- Where
- Colombia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Healthy Volunteer, Malaria
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Background: Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body.
- Trial name
- NCT07859800
- Testing
- 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria, Vivax
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
In this area of Greater Mekong Subregion (GMS), vivax malaria is the most common kind of malaria. It can stay very long in the liver, and come out later to make another episode of illness.
- Conditions
- Malaria, Malaria, Vivax, Plasmodium Vivax Malaria
- Trial name
- ACTQ (NCT05788094)
- Testing
- Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose), Chloroquine plus Tafenoquine (450 mg adult dose), Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
- Where
- Thailand
- Volunteers
- 606 people
- Sponsor
- Shoklo Malaria Research Unit
Malaria, Vivax, G6PD Deficiency
Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
This is an observational study carried out in Brazil in patients with P. vivax malaria. The study will be carried out in the municipalities of Manaus (state of Amazonas) and Porto Velho (state of Rondônia).
- Trial name
- Trust (NCT05096702)
- Testing
- Tafenoquine, Primaquine
- Where
- 41 sites in Brazil
- Volunteers
- 16,000 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Malaria
Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults
Background: Malaria is a disease carried by mosquitoes in tropical countries around the world. It can cause symptoms like fever, body aches, and weakness.
- Trial name
- NCT05913973
- Testing
- Pvs230D1-EPA/Matrix-M
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Vivax
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
This is an open-label, single-centre, non-randomised, first-in-human Phase Ia study to assess the safety and immunogenicity of the Pvs25-IMX313 vaccine, administered in Matrix-M1 adjuvant.
- Trial name
- NCT05270265
- Testing
- Pvs25-IMX313/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax
Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection
This study specifically seeks to provide data on the safety, tolerability and pilot efficacy of short course, high dose primaquine treatment in Papua New Guinean children aged 5-10 years, in a cross-sectional study design.
- Trial name
- NCT02364583
- Testing
- Primaquine
- Where
- Papua New Guinea
- Volunteers
- 150 people
- Sponsor
- Papua New Guinea Institute of Medical Research
Malaria
Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day
- Trial name
- NCT01524341
- Testing
- KAE609
- Where
- 3 sites in Thailand
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Plasmodium Vivax Malaria
Papua New Guinean Duffy Negativity And Vivax Malar
The purpose of this study is to learn more about vivax malaria in very young children, how the growth of children is affected by malaria infections, and how inherited traits protect children from getting malaria.
- Trial name
- NCT00138489
- Where
- Papua New Guinea
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers
The purpose of the study is to assess if the antimalarial drugs Dihydroartemisinine + Piperaquine (DP) are effective in preventing malaria infection for forest ranger
- Trial name
- PREMAL (NCT02788864)
- Testing
- Arterakine (DHA/piperaquine)
- Where
- Vietnam
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Malaria
Effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) Model in Myanmar
In Myanmar, community health workers, known as malaria volunteers, have played a key role in reducing the malaria burden in the malaria control phase, providing essential malaria services in rural areas where the coverage of…
- Trial name
- NCT04695886
- Testing
- Community-delivered Integrated Malaria Elimination (CIME) intervention model
- Volunteers
- 6,440 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria, Vivax
Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
A clinical trial aimed to standardize a vivax sporozoite infection model in human volunteers was conducted at the Malaria Vaccine and Drug Development Center (MVDC) in collaboration with the Immunology Institute at Valle State…
- Trial name
- ChallengeII (NCT01083095)
- Testing
- Sporozoite Challenge Model for Plasmodium vivax in Humans
- Where
- Colombia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Plasmodium Vivax Malaria
Southeast Asia Dose Optimization of Tafenoquine
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the…
- Trial name
- SEADOT (NCT04704999)
- Testing
- Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg
- Where
- 6 sites in Cambodia, Indonesia and 3 more
- Volunteers
- 820 people
- Sponsor
- University of Oxford
Plasmodium Vivax
Phenotyping and Genotyping of Duffy Antigen
Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control.
- Trial name
- DARC (NCT05527119)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France